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Methods: We included 9 patients with typical atrial flutter for
whom mapping and ablation of the CTI was done using Carto
mapping as the sole guiding modality. Zero fluoroscopy was
achieved in all of them. Another group of 9 matched patients
whose ablations were done using the traditional method (i.e.
fluoroscopy and Carto guidance) were included as a control.
Results: Both groups had similar baseline characteristics. The
total fluoroscopy time and radiation dose in the control group
were 12.8 ± 4.8 minutes, 230.2 ± 131.9 mGy, respectively.
The zero-fluoroscopy group were done while wearing no lead
aprons. The average total procedure time was 114.8 ± 16.9
minutes in the zero-fluoroscopy group, significantly less than
that of the control group (138.6 ± 24.3 minutes; P=0.0286). The
total radiofrequency time was similar in both groups (15.2 ±
7.4 minutes in zero-fluoroscopy group vs 16 ± 2.9 minutes in
control group; P=0.9294). Bidirectional block was achieved in
all patients of both groups. No complications were encountered
in either group.
Conclusion: To our knowledge, this is the first study of a zerofluoroscopic approach using the Carto mapping system for
ablation of the cavotricuspid isthmus in the United States. The
approach is feasible and effective in achieving bidirectional
block with less average total procedure time.
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Background: Anthracycline and trastuzumab are common
breast cancer treatments. While improving survival, they elevate
risk of congestive heart failure. The incidence of cardiotoxicity
(CTx) with these therapies varies in the literature from 10%
to 59%, higher than those reported in clinical trials (4%–
10%) that excluded patients with preexisting cardiovascular
comorbidities. Studies have failed to establish consensus on the
risk factors for CTx associated with these therapies.
Purpose: We aim to determine the incidence and risk factors of
CTx in breast cancer patients treated with anthracycline and/or
trastuzumab at Aurora Health Care.
Methods: A retrospective review of patients with breast
cancer who received anthracycline and/or trastuzumab from
2002 to 2011 yielded a total of 2,383 patients. Patients with
a left ventricular ejection fraction (LVEF) recorded prior to
treatment and at least one follow-up LVEF were included in
analysis (n=319, 13.4% of total cohort). Database queries
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and electronic medical records review (assisted by an inhouse natural language processing tool) retrieved data
on demographics, comorbidities, congestive heart failure
symptoms, oncological treatments and LVEF. The study
outcome was CTx, defined as a ≥ 10% decrease in LVEF to
a level of < 55%. Chi-squared and Fisher’s exact tests were
used for categorical variables to test differences in patient
characteristics by CTx status (yes/no). Multivariate logistic
regression analyses examined the association between risk
factors and CTx.
Results: Average age of the patients was 54.9 ± 12.1 years;
the cohort was comprised of 50.5% with obesity, 44.2% with
smoking history and 47.3% with hypertension. A total of 79
patients developed CTx, an incidence of 24.8%. Multivariable
analysis identified divorced/widowed marital status (odds ratio
[OR]: 2.70, 95% confidence interval [CI]: 1.26–5.77), history of
structural/electrophysiological (EP) cardiac disease (OR: 2.66,
95% CI: 1.24–5.70) and combined anthracycline-trastuzumab
therapy (OR: 2.92, 95% CI: 1.48–5.77) as significant risk
factors for CTx.
Conclusion: The incidence of CTx was greater in a community
setting for which cardiac history and comorbidities are more
diverse than in clinical trials. Consistent with prior literature,
our study identified combined treatment with anthracycline and
trastuzumab as a risk factor for CTx. Our study also suggests
divorced/widowed marital status and prior structural/EP cardiac
disease as additional risk factors for CTx. Further prospective
studies are warranted for verification. We advocate for pre- and
posttreatment cardiac monitoring of patients receiving these
two therapies.
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Background: Several studies have compared international
graduates on measures of performance, quality and satisfaction.
No studies have compared internally versus externally hired
graduates in relation to these measures.
Purpose: To identify if there is a difference in hiring patterns
and care management (CM)/patient satisfaction (PS) scores
between internal and external graduate hires.
Methods: We conducted a quality improvement study on
graduates hired by Aurora Health Care from Jan. 1, 2006,
to Dec. 14, 2015. CM scores were determined based on hire
date. PS scores were calculated based on the calendar year,
regardless of exact hire date. PS scales for scoring changed
in mid-2010. Hired graduates with no CM and PS scores, as
well as those with less than one year of employment, were
excluded. Means were compared using two-sample t-tests
and regression analysis. Categorical variables were analyzed
using chi-squared and Fisher’s exact test, as appropriate.
Results: Study population (N=108) characteristics included:
mean age 38.0 years, 62.0% female gender and 56.5%
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